蛋白酶体抑制剂相关肺动脉高压的特征与结局
基于法国肺动脉高压注册登记与VIGIAPATH项目2004至2023年数据,识别11例蛋白酶体抑制剂相关肺动脉高压事件病例,其中卡非佐米6例、硼替佐米5例;结合WHO药物警戒数据库的不均衡性分析和随机对照试验荟萃分析,发现卡非佐米报告信号强于硼替佐米,提示蛋白酶体抑制剂可能诱发肺动脉高压,治疗期间需密切监测。
要点
- 蛋白酶体抑制剂治疗期间可能出现肺动脉高压,卡非佐米信号强于硼替佐米。
- 事件病例中位年龄61岁,女性与男性比为2.7:1,用药至诊断中位间隔6个月。
- 诊断时6例为NYHA功能III/IV级,伴严重血流动力学损害,需密切监测。
核心结论
- 蛋白酶体抑制剂可能在治疗中诱发肺动脉高压,卡非佐米信号强于硼替佐米,患者应密切监测。
研究设计与样本
- 基于法国肺动脉高压注册登记和VIGIAPATH项目2004至2023年的事件病例分析。
- 同时进行WHO全球数据库VigiBase的药物警戒不均衡性分析。
- 并进行随机对照试验的荟萃分析。
主要发现
- 识别11例蛋白酶体抑制剂相关肺动脉高压事件病例,卡非佐米6例、硼替佐米5例,女性与男性比2.7:1,中位年龄61岁。
- 蛋白酶体抑制剂首次暴露至肺动脉高压诊断的中位间隔为6个月。
- 4例患者死亡,其中2例死于右心衰竭,1例死于呼吸窘迫,1例死因未知。
- 诊断时6例为NYHA功能III/IV级,中位平均肺动脉压39 mmHg、心脏指数2.45 L·min-1·m-2、肺血管阻力7.2 WU。
- WHO药物警戒数据库自2013年报告169例蛋白酶体抑制剂相关肺高压病例,卡非佐米在各病例定义或对照组下均有显著不均衡报告信号,硼替佐米信号不一致。
临床怎么用
- 使用卡非佐米或硼替佐米治疗的患者应警惕肺动脉高压的发生,并在治疗期间密切监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary arterial hypertension (PAH) has been described in patients treated with proteasome inhibitors (PIs). Our objective was to evaluate the association between PIs and PAH. METHODS: Characteristics of incident PAH cases previously treated with carfilzomib or bortezomib were analysed from the French pulmonary hypertension registry and the VIGIAPATH programme from 2004 to 2023, concurrently with a pharmacovigilance disproportionality analysis using the World Health Organization (WHO) global database (VigiBase) and a meta-analysis of randomised controlled trials. RESULTS: 11 incident cases of PI-associated PAH were identified (six with carfilzomib and five with bortezomib) with a female:male ratio of 2.7:1, a median age of 61 years, and a median delay between PI first exposure and PAH of 6 months. Four patients died (two from right heart failure, one from respiratory distress and one from an unknown cause). At diagnosis, six were in New York Heart Association Functional Class III/IV with severe haemodynamic impairment (median mean pulmonary arterial pressure 39 mmHg, cardiac index 2.45 L·min-1·m-2 and pulmonary vascular resistance 7.2 WU). In the WHO pharmacovigilance database, 169 cases of PH associated with PI were reported since 2013 with significant signals of disproportionate reporting (SDR) for carfilzomib, regardless of the definition of cases or control group. However, SDR for bortezomib were inconsistent. The systematic review identified 17 clinical trials, and carfilzomib was associated with a significantly higher risk of dyspnoea, severe dyspnoea and PH compared with bortezomib. CONCLUSION: PIs may induce PAH in patients undergoing treatment, with carfilzomib emitting a stronger signal than bortezomib, and these patients should be monitored closely.
引用
- Grynblat J, Khouri C, Hlavaty A, et al. Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors. Eur Respir J. 2024. PMID: 38697649. doi:10.1183/13993003.02158-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。